Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Bocidelpar; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anniston, Alabama • Rialto, California • Miami, Florida + 1 more

Conditions: Stroke
Interventions: Tracking training; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Product B® IsaGenesis®, IsaGenesis®; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy
Interventions: Fenofibric Acid 105 mg Tablet; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Abdominal Aortic Aneurysm
Interventions: Ovation® Abdominal Stent Graft Platform; Device
Lead sponsor: TriVascular, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Phoenix, Arizona • Houston, Texas

Conditions: Healthy Volunteers Food Interaction Study
Interventions: AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Propranolol Hydrochloride Extended-Release Capsules 160 mg, Inderal® LA Capsules 160 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: PreDiabetes
Interventions: Glucagon, Glucose; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: Cold exposure, Normal temperature, Fixed diet, Ad libitum diet, Fasting; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Contraception, Hypogonadism
Interventions: Oral Testosterone, Leuprolide (Lupron), Dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cannabis Use
Interventions: "All Natural" descriptor, "Gluten-free" descriptor, "Vegan" descriptor, "100% Organic" descriptor, "Handcrafted" descriptor, "Made with live resin" descriptor, "Fast-acting" descriptor, "Relax" descriptor, "Energy Boost" descriptor, No descriptor (control); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2,521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Hepatitis C
Interventions: telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: To Determine the Bioequivalence Under Fasting Conditions
Interventions: Oxandrolone, Oxandrin; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteers
Interventions: Brensocatib, Clarithromycin; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Hydromorphone Hydrochloride tablet 8 mg, Dilaudid® tablet 8 mg; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Type 2 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 31
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 26 more

Conditions: Healthy, Young Adults
Interventions: RLIC - 5 cycles, RLIC - 4 Cycles, RLIC - 3 Cycles, Sham conditioning, Balance training, Arm training, Sequence production training; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Lymphoblastic Leukemia
Interventions: Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Chronic Kidney Disease
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Healthy
Interventions: [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostatic Neoplasms
Interventions: MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Hennepin County Medical Center, Minneapolis; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Movement Velocity Effect on Cortical Reorganization and Finger Function in Stroke

Relative Bioavailability of Two Different Milk Thistle Formulations

Four Arm Food Effect Study of Fenofibric Acid Tablets

LIFE Study: Least Invasive Fast-Track EVAR

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

Food Intake Response to Short-Term Modifications of Metabolism in Humans

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

Cannabis Edibles Packaging Descriptors Experiment

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement

Aerobic and Strengthening Exercise for Acute Leukemia

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study